Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.
Vijay Maruti PatilVanita NoronhaNandini Sharrel MenonRahul RaiAtanu BhattacharjeeAjay SinghKavita NawaleShweta JogdhankarRupali TambeSachin DhumalRiddhi SawantMitali AloneDevanshi KarlaZoya PeelayShruti PathakArun BalajiSuman KumarNilendu PurandareArchi AgarwalAmeya D PuranikAbhishek MahajanAmit JanuGunjesh Kumar SinghNeha MittalSubhash YadavShripad D BanavaliKumar PrabhashPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
To our knowledge, this is the first-ever randomized study to demonstrate that the addition of low-dose nivolumab to metronomic chemotherapy improved OS and is an alternative standard of care for those who cannot access full-dose checkpoint inhibitors.